BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

Core Insights - BioCardia, Inc. is a global leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases [2] - The company will present at the CSI Focus Devices in Heart Failure conference in Frankfurt, Germany, on December 5, 2025 [1] - The presentation will focus on "Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection" [1] Company Overview - BioCardia is headquartered in Sunnyvale, California, and specializes in biotherapeutic platforms, including CardiAMP® autologous and CardiALLO™ allogeneic cell therapies [2] - The company has three clinical stage product candidates in development, supported by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms [2] Event Details - The CSI Focus D-HF conference will cover advancements in device-based therapy for heart failure, including ventricle restoration strategies and monitoring systems [1] - The session featuring BioCardia's CEO will take place from 10:30 to 11:30 CET [1]